EN DE
Watch CryoCell International Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CryoCell International Inc (CCEL) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of CryoCell International Inc stock $9.85, price $4.85, upside +103.1%, quality 55 out of 100. Rating: strongly undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CI CryoCell International Inc logo Some data Nov 9, 2026

CryoCell International Inc

CCEL · US

Cheap (51% below fair value) and solid company, but price moving sideways: meets 2 of 3 rules.

Get notified free when this changes
Fair value $9.85 · Strongly undervalued 
Generates free cash flow 
Even on cautious assumptions the value is 51% above the price ($7.30). 
Quality 55/100 
Price moving sideways (no uptrend) 
Negative equity (buybacks among others) 
Mixed vs. peers (6/11) 
Some data 
Weak Growth (revenue 5y +0.3 %/yr in USD) 
Loss-making · -6.3% net margin (TTM) 
Narrow moat 42/100 · thin data
Watch CryoCell International Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$11.36 $2.71 Fair Value $9.85 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range $2.71 – $11.36 · fair‑value band $7.30 – $12.40 · the $4.85 price screens below the $9.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.

Follow CryoCell International in your weekly email

Every Wednesday you see whether CryoCell International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States.

Show moreShow less

The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use.

It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions.

It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Stock analysis

CryoCell International Inc (CCEL) currently trades at $4.85, while our model-based Fair Value estimate is $9.85, implying the stock looks roughly 51% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $12.55 per share, and 12 of the 12 models we run sit above the $4.85 price.

Bear case: the Earnings-Based group reads lowest at $5.21, and 0 of the 12 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $7.30 (bear) to $12.40 (bull), the price of $4.85 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

CryoCell International Inc reported revenue of $31.6M in FY2025 versus $28.9M in FY2021, a compound +2.2%/yr. Reported net income was −$2.4M in FY2025.

Key figures

Market cap $39.1M Micro · P/S ratio 1.33 · EPS (TTM) $−0.2500 · Dividend yield 7.8% · Net margin −6.3% · Return on equity 129% · Return on assets (EBIT) 1.2% (5-year average) · Operating margin 28.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 10% below its 52-week high and 68% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 103%, CCEL screens cheaper than that median.

Fair Value models

Bear $7.30 Fair Value $9.85 Bull $12.40
Price $4.85 · Upside +103.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $9.54 $16.03 $26.40 78
Growth DCF $9.70 $15.38 $23.87 77
5Y EBITDA Exit $7.37 $12.17 $17.77 74
All 12 models by family
DCF Models
FCF DCF $9.54 $16.03 $26.40 78
5Y Revenue Exit $6.04 $9.65 $14.19 72
5Y EBITDA Exit $7.37 $12.17 $17.77 74
10Y Revenue Exit $7.00 $10.65 $15.49 66
10Y EBITDA Exit $8.04 $12.44 $18.30 68
Earnings-Based
EPV $4.31 $5.21 $6.01 74
Multiples
EV/EBIT $7.30 $9.85 $12.40 66
EV/EBITDA $7.73 $10.42 $13.12 67
EV/Revenue $5.11 $7.45 $9.79 53
Growth DCF
Growth DCF $9.70 $15.38 $23.87 77
Rev-Margin DCF $6.04 $9.72 $14.07 72
Economic Profit
ROIC Compounder $4.31 $5.21 $6.01 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 55/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 27
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 79
Do the profits arrive as real cash?
Financial strength 5
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 47
How calm the share price moves, does not count
Price momentum 63
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 67
Distance to the 52-week high, does not count
New shares 88
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−1.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Start year 2020 (pandemic). Over 10 years: +4.1% a year
Revenue growth 29 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.4%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −9.5% a year for the price.

Watch CCEL, get fair value alerts →

Compare CryoCell International Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 248 stocks

Beats the industry median on 6/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 55 · Below median
Fair Value upside +103.1% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −3.9% · Bottom 25%
Net margin (12 months) −6.3% · Bottom 25%
Operating margin (12 months) 28.0% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Bottom 25%
Dividend yield (12 months) 7.8% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 1.26× · Cheaper than median
Price / free cash flow (fiscal year) 7.5× · Cheapest 25%
EV/EBITDA 40.5× · Priciest 25%
PEG 1.34× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 34
FUTURE (revenue growth)0 · sector 32
PAST (return on equity)0 · sector 31
HEALTH (low debt)0 · sector 90
DIVIDEND (yield)100 · sector 38

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $46.04 +109% vs CCEL
DaVita Inc DVA $174.56 $218.90 +25% vs CCEL
Aier Eye Hospital Group 300015 ¥8.84 ¥10.88 +23% vs CCEL
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs CCEL
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs CCEL
Encompass Health Corporation EHC $140.99 $94.81 −33% vs CCEL
IHH Healthcare Berhad 5225 7.93 MYR 5.23 MYR −34% vs CCEL
Fresenius SE FRE €53.62 €34.77 −35% vs CCEL
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,526 ₹5,234 −39% vs CCEL
Dr. Sulaiman Al Habib Medical Services Group 4013 213.60 SAR 109.45 SAR −49% vs CCEL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CryoCell International Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CryoCell International Inc Fair Value". https://www.fairvalue-calculator.com/stock/CCEL

Frequently asked questions

Is CryoCell International Inc (CCEL) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $9.85 versus a price of $4.85, about +103% upside (undervalued).
What is the fair value of CCEL?
Our model-based fair value for CryoCell International Inc is $9.85 (as of Nov 9, 2026), built from audited fundamentals. The current price: $4.85.
What is the quality score of CCEL?
CryoCell International Inc has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CryoCell International Inc (CCEL)?
Our model-based price target is the fair value of $9.85 (as of Nov 9, 2026) from 12 valuation models. Cautious scenario $7.30, optimistic scenario $12.40. It is a calculation from audited fundamentals, not an analyst target.
What is the CryoCell International Inc stock forecast for 2026?
Our models put fair value at $9.85, about +103% upside versus a price of $4.85 (undervalued). Cautious scenario $7.30, optimistic scenario $12.40. The calculation is refreshed regularly with new filings.
What is the revenue of CryoCell International Inc (CCEL)?
CryoCell International Inc reported trailing-twelve-month revenue of about $31.1M (latest available figure, as of Nov 9, 2026).
Does CryoCell International Inc pay a dividend?
CryoCell International Inc currently shows a dividend yield of 7.82% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of CryoCell International Inc (CCEL)?
CryoCell International Inc has a dividend yield of 7.8%.
What growth is priced into CryoCell International Inc (CCEL)?
For today's price to be fair in a discounted-cash-flow model, CryoCell International Inc would have to grow free cash flow by -7.4 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.3 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of CCEL use?
Our models discount CryoCell International Inc at 8.7 %: a base by market capitalisation (nano), damped by beta 0.59, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CryoCell International Inc that is -7.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has CryoCell International Inc (CCEL) delivered so far?
Over the past 5 years revenue at CryoCell International Inc grew +0.3 % a year. The price currently implies free-cash-flow growth of -7.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of CryoCell International Inc (CCEL) growing?
The median revenue growth in the sector is +5.8 % a year. That is the yardstick for the growth priced into CryoCell International Inc (-7.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of CryoCell International Inc (CCEL)?
The free-cash-flow yield on the price is 13.42 %: that much free cash flow CryoCell International Inc produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of CryoCell International Inc (CCEL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CryoCell International Inc it is $9.85 per share (as of Nov 9, 2026), against a price of $4.85. It is the blended result of 12 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit).
Is CryoCell International Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, CCEL trades below its calculated fair value: price $4.85, fair value $9.85, a gap of about +103% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CCEL?
No. The price is what the market pays today ($4.85); the fair value is what the company's own numbers justify ($9.85). For CryoCell International Inc the two are $5.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is CryoCell International Inc worth?
The market values CryoCell International Inc at about $39.1M (market capitalisation, as of Nov 9, 2026). Per share that is $4.85; our models calculate a fair value of $9.85 per share.
What do the bullish and bearish scenarios say about CCEL?
Our models span a range for CryoCell International Inc: cautious scenario $7.30, base $9.85, optimistic $12.40 per share (as of Nov 9, 2026, price $4.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of CCEL?
The PEG ratio of CryoCell International Inc is 1.34 (P/E divided by earnings growth, as of Nov 9, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of CryoCell International Inc (CCEL)?
Balance-sheet figures for CryoCell International Inc (as of Nov 9, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is CCEL from its 52-week high?
CryoCell International Inc trades at $4.85, about 10% below its 52-week high of $5.40 and 68% above the low of $2.89 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $9.85 is for.
Which stocks are comparable to CryoCell International Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CryoCell International Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $4.85, calculated fair value $9.85 (+103%), Quality Score 55/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CCEL calculated?
We run CryoCell International Inc through 12 models from 5 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $9.85 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. CryoCell International Inc currently trades 51% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CryoCell International Inc (CCEL)?
The closing price on Nov 13, 2026 was $4.85. Our model-based fair value is $9.85, about +103% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CryoCell International Inc right now?
The price is below even our cautious bear case ($7.30). The market is more pessimistic than our downside scenario. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.

Key figures of CryoCell International Inc

How large is the market capitalisation of CryoCell International Inc (CCEL)?
The market capitalisation of CryoCell International Inc is $39.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CryoCell International Inc (CCEL)?
The price-to-sales ratio of CryoCell International Inc is 1.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CryoCell International Inc (CCEL)?
Earnings per share at CryoCell International Inc are $−0.2500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of CryoCell International Inc (CCEL)?
The dividend yield of CryoCell International Inc is 7.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of CryoCell International Inc (CCEL)?
The net margin of CryoCell International Inc is −6.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CryoCell International Inc (CCEL)?
The return on equity (ROE) of CryoCell International Inc is 129% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CryoCell International Inc (CCEL)?
On an EBIT basis the return on assets of CryoCell International Inc is 1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CryoCell International Inc (CCEL)?
The operating margin of CryoCell International Inc is 28.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at CryoCell International Inc (CCEL)?
Earnings per share at CryoCell International Inc are growing +75.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does CryoCell International Inc (CCEL) carry?
The net debt of CryoCell International Inc is $2.9M (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CryoCell International Inc in the live analysis

One click puts CryoCell International Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.